Centrally Acting Antiobesity Products

DrugDrug NameDrug Indication
DB00191PhenterminePhentermine is indicated, alone or in combination with topiramate, as a short-term adjunct, not pass a few weeks, in a regimen of weight reduction based on exercise, behavioral modifications and caloric restriction in the management of exogenous obesity for patients with an initial body mass index (BMI) greater than 30 kg/m2 or greater than 27 kg/m2 in presence of other risk factors such as controller hypertension, diabetes or hyperlipidemia.[FDA label] Exogenous obesity is considered when the overweight is caused by consuming more food than the person activity level warrants. This condition commonly causes an increase in fat storage. It is an epidemic condition in the United States where over two-thirds of adults are overweight or obese and one in three Americans is obese. In the world, the incidence of obesity has nearly doubled.[A174391]
DB00574FenfluramineFor the management of exogenous obesity as a short-term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction.
DB00579MazindolUsed in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m2) or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.
DB00937DiethylpropionUsed in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.
DB01105SibutramineFor the treatment of obesity.
DB01191DexfenfluramineFor the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet
DB01486CathineUsed to decrease appetite.
DB04871LorcaserinFor the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.
DB13561ClobenzorexNot Available
DB00704NaltrexoneUsed as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
DB01156BupropionFor the treatment of depression and as aid to smoking cessation.
DB01364EphedrineEphedrine commonly used as a stimulant, appetite suppressant, concentration aid, decongestant, and to treat hypotension associated with anaesthesia.
DrugDrug NameTargetType
DB00191PhentermineSodium-dependent noradrenaline transportertarget
DB00191PhentermineSodium-dependent dopamine transportertarget
DB00191PhentermineAmine oxidase [flavin-containing] Atarget
DB00191PhentermineAmine oxidase [flavin-containing] Btarget
DB00191PhentermineSodium-dependent serotonin transportertarget
DB00191PhenterminePro-neuropeptide Ytarget
DB00191PhentermineCytochrome P450 3A4enzyme
DB00574Fenfluramine5-hydroxytryptamine receptor 2Ctarget
DB00574Fenfluramine5-hydroxytryptamine receptor 2Btarget
DB00574FenfluramineCytochrome P450 2D6enzyme
DB00574FenfluramineSodium-dependent serotonin transportertarget
DB00574Fenfluramine5-hydroxytryptamine receptor 2Atarget
DB00579MazindolSodium-dependent noradrenaline transportertarget
DB00579MazindolSodium-dependent dopamine transportertarget
DB00579MazindolSodium-dependent serotonin transportertarget
DB00579MazindolSynaptic vesicular amine transportertarget
DB00937DiethylpropionSodium-dependent noradrenaline transportertarget
DB00937DiethylpropionSodium-dependent dopamine transportertarget
DB01105SibutramineSodium-dependent serotonin transportertarget
DB01105SibutramineSodium-dependent noradrenaline transportertarget
DB01105SibutramineCytochrome P450 3A4enzyme
DB01105SibutramineSodium-dependent dopamine transportertarget
DB01191DexfenfluramineSodium-dependent serotonin transportertarget
DB01191Dexfenfluramine5-hydroxytryptamine receptor 2Ctarget
DB01191DexfenfluramineCytochrome P450 2D6enzyme
DB01191DexfenfluramineCytochrome P450 1A2enzyme
DB01191DexfenfluramineCytochrome P450 2E1enzyme
DB04871Lorcaserin5-hydroxytryptamine receptor 2Ctarget
DB04871LorcaserinCytochrome P450 1A2enzyme
DB04871LorcaserinCytochrome P450 2A6enzyme
DB04871LorcaserinCytochrome P450 2B6enzyme
DB04871LorcaserinCytochrome P450 2C19enzyme
DB04871LorcaserinCytochrome P450 2D6enzyme
DB04871LorcaserinCytochrome P450 3A4enzyme
DB04871LorcaserinDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB04871LorcaserinCytochrome P450 1A1enzyme
DB00704NaltrexoneMu-type opioid receptortarget
DB00704NaltrexoneKappa-type opioid receptortarget
DB00704NaltrexoneDelta-type opioid receptortarget
DB00704NaltrexoneHCG20471, isoform CRA_ctarget
DB00704NaltrexoneUDP-glucuronosyltransferase 1-1enzyme
DB01156BupropionSodium-dependent dopamine transportertarget
DB01156BupropionSodium-dependent noradrenaline transportertarget
DB01156BupropionCytochrome P450 2B6enzyme
DB01156BupropionCytochrome P450 2D6enzyme
DB01156BupropionAlpha-1-acid glycoprotein 1carrier
DB01156BupropionNeuronal acetylcholine receptor subunit alpha-3target
DB01156BupropionCytochrome P450 2A6enzyme
DB01156BupropionCytochrome P450 2C8enzyme
DB01156BupropionCytochrome P450 2C9enzyme
DB01156BupropionCytochrome P450 2E1enzyme
DB01156BupropionCytochrome P450 3A4enzyme
DB01156BupropionSolute carrier family 22 member 2transporter
DB01364EphedrineAlpha-1A adrenergic receptortarget
DB01364EphedrineSodium-dependent noradrenaline transportertarget
DB01364EphedrineSynaptic vesicular amine transportertarget